首页> 美国卫生研究院文献>Malaria Journal >Optimal designs for population pharmacokinetic studies of oral artesunate in patients with uncomplicated falciparum malaria
【2h】

Optimal designs for population pharmacokinetic studies of oral artesunate in patients with uncomplicated falciparum malaria

机译:单纯性恶性疟疾患者口服青蒿琥酯的群体药代动力学研究的优化设计

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundCurrently, population pharmacokinetic (PK) studies of anti-malarial drugs are designed primarily by the logistical and ethical constraints of taking blood samples from patients, and the statistical models that are fitted to the data are not formally considered. This could lead to imprecise estimates of the target PK parameters, and/or designs insufficient to estimate all of the parameters. Optimal design methodology has been developed to determine blood sampling schedules that will yield precise parameter estimates within the practical constraints of sampling the study populations. In this work optimal design methods were used to determine sampling designs for typical future population PK studies of dihydroartemisinin, the principal biologically active metabolite of oral artesunate.
机译:背景技术目前,抗疟疾药物的人群药代动力学(PK)研究主要是根据从患者身上采集血液样本的后勤和伦理学约束设计的,尚未正式考虑适合该数据的统计模型。这可能导致目标PK参数的估算不准确,和/或设计不足以估算所有参数。已开发出最佳设计方法来确定血液采样计划,该计划将在对研究人群进行采样的实际限制内得出精确的参数估计值。在这项工作中,使用最佳设计方法来确定典型的未来人口PK双氢青蒿素(口服青蒿琥酯的主要生物活性代谢物)研究的抽样设计。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号